Ads
related to: treatment for multiple sclerosis- Treatment FAQs
See Frequently Asked
Questions. Get The Answers.
- Relapsing MS Treatment
Learn About A RMS
Treatment Option.
- Patient Stories
See What Real Patients
Are Saying About This Treatment.
- Financial Resources
See Financial & Savings Info.
Learn About Savings Options.
- Patient Resources
Download Resources To
Learn More About Treatment.
- Getting Started
Sign Up For More Info On
How To Get Started.
- Treatment FAQs
Search results
Results From The WOW.Com Content Network
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease, MS disrupts the nervous system's ability to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
In February 2016, the US Food and Drug Administration (FDA) granted breakthrough therapy designation for primary progressive multiple sclerosis. [21] In March 2017, the FDA approved ocrelizumab for relapsing-remitting and primary-progressive multiple sclerosis. It is the first FDA-approved treatment for the primary progressive form.
In the United states, natalizumab is indicated for the treatment of multiple sclerosis and Crohn's disease. [1] [9] It is indicated to treat clinically isolated syndrome – a single, first occurrence of multiple sclerosis symptoms; relapsing-remitting disease – a type of multiple sclerosis that occurs when people have episodes of new neurological symptoms followed by periods of stability ...
ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program Award Will Advance ACADIA's Selective ER-Beta Agonist as a Potential New Neuroprotective ...
Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, used for the treatment of multiple sclerosis. [4] Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction.
Ads
related to: treatment for multiple sclerosis